Dipeptidylpeptidase-4 (DPP-4) inhibitors (Formulary)

For use in type 2 diabetes, refer to: Achieving Control in Type 2 diabetes

ALOGLIPTIN - (First line)

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 6·25mg, 12·5mg, 25mg

Dosage:

As per SMC 937/14: For adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
SMC restriction: dual therapy
  • In combination with metformin, when metformin alone, together with diet and exercise does not provide adequate glycaemic control in patients for whom the addition of a sulfonylurea is inappropriate.
  • In combination with a sulfonylurea, when sulfonylurea alone, together with diet and exercise does not provide adequate glycaemic control in patients for whom the addition of metformin is inappropriate due to contra-indications or intolerance.

LINAGLIPTIN

Important: Therapy notes

First-line DPP-4 inhibitor of choice in any degree of renal impairment.

Important: Formulation and dosage details

Formulation:

Tablets 5mg

Editorial Information

Document Id: F174